Market Size of Tinea Pedis Treatment Industry
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 1.38 Billion |
| Market Size (2029) | USD 1.69 Billion |
| CAGR (2024 - 2029) | 4.19 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Tinea Pedis Treatment Market Analysis
The Tinea Pedis Treatment Market size is estimated at USD 1.38 billion in 2024, and is expected to reach USD 1.69 billion by 2029, growing at a CAGR of 4.19% during the forecast period (2024-2029).
During the COVID-19 pandemic, the demand for tinea pedis treatment drugs rose due to increasing concerns about the mortality of patients with COVID-19. Fungal comorbidities in COVID-19 lead to higher mortalities compared to COVID-19 patients without these comorbidities. For instance, according to an article published by Nature Microbiology in August 2022, COVID-19-associated invasive fungal infections were a significant complication in a substantial number of critically ill, hospitalized patients. Hence, the COVID-19 pandemic affected the market significantly in its preliminary phase. However, as the pandemic has currently subsided, the studied market is expected to have stable growth over the forecast period of the study.
The major factor attributing to the growth of the market is the increase in the prevalence of fungal infections. Mycotic diseases are global in distribution, but the maximum cases are recorded from tropical and subtropical countries. As the number of patients increases, the market also grows. Furthermore, the increasing R&D programs and funding for the same are boosting the market growth.
For instance, according to an article updated by NCBI in July 2022, it is estimated that about 10% of the total population is affected by dermatophyte infections of the toe clefts. The most common reason for this is wearing occlusive shoes for long periods. The report also stated that the sharing of washing facilities is likely to increase the chances of infection as the incidence of tinea pedis is observed to be higher among those using community baths, showers, and pools. Tinea pedis is also said to be more common in adult males than in females. In addition to this, the rise in immunocompromised patients is also another factor that is expected to fuel market growth.
Furthermore, the increased R&D activities for the treatment of tinea pedis have been boosted by the rise in the prevalence rate of infectious disorders caused by bacteria, viruses, and fungi, which is driving the market. Around the world, anti-microbial research is gaining traction, and many companies have already initiated R&D activities, which is further expected to boost the growth of the studied market as fungal infections are also part of anti-microbial research activities. For instance, in August 2022, Forbion, announced the USD 70 million financing of F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections with a high unmet medical need.
Therefore, a rise in the prevalence of tinea pedis and a rise in research and development on fungal treatment, among others, are the factors expected to drive the market growth. However, the lack of awareness of the treatment and stringent approval regulations constrain the market growth.
